The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > COLUMN
COLUMN
-
Successful People Have the Best Information
September 24, 2014
-
Is Your Body Language Louder than Your Speech?
August 25, 2014
-
Taking Pride in Small Things Makes Big Things Possible
July 25, 2014
-
It’s Moments Like These
June 27, 2014
-
How to Hire a Medical Doctor Who Is a Business Person First
May 23, 2014
-
Transforming from a Key Opinion Leader to a Key Account
April 25, 2014
-
Emerging Immunotherapy of Cancer: 2
April 11, 2014
-
Emerging Immunotherapy of Cancer: 1
April 10, 2014
-
Sun Tzu and the Art of Interviewing
March 18, 2014
-
2014: Year of the (Trojan) Horse – CROs Are about to Take the Pharma Industry by Storm
February 21, 2014
-
The Time Is Now for Medical Affairs
January 17, 2014
-
Blue Ocean Recruiting
December 20, 2013
-
Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 1
November 7, 2013
-
A World of Opportunity for the Brave
November 1, 2013
-
Does HR Have an Image Problem?
September 20, 2013
-
Learn How to Give a Great Presentation and You May Break the “Gaijin Ceiling” to the Board Room at Headquarters
August 21, 2013
-
Watch out for the Gorilla when Hiring Talent
July 19, 2013
-
Great Leaders Are Happy to Eat Humble Pie and Give the Credit to Others
June 21, 2013
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…